Iodopol (Sodium Iodide (131i))

After oral ingestion, sodium iodide (131I) is taken up by thyroid follicular cells via the sodium‑iodide symporter. The isotope then emits beta radiation that causes localized DNA damage, leading to selective destruction of thyroid cells while largely sparing surrounding tissues.

The prescribed activity of Iodopol is determined by the treating physician based on individual factors such as patient weight, thyroid uptake measurements, disease severity and clinical goals. Dosing regimens vary and are tailored to each patient’s specific therapeutic needs.

Safety of Iodopol in pregnant or lactating women has not been established. Because the radioactive iodine can cross the placenta and be secreted in breast milk, it is generally contraindicated unless the potential benefit outweighs the risk and the decision is made by a specialist.

To order Iodopol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Iodopol, as a radioactive iodine preparation, offers a targeted approach that destroys thyroid tissue from within, unlike antithyroid drugs that block hormone synthesis. Compared with non‑radioactive therapies, it typically requires fewer treatment cycles and can be used after surgery for cancer. However, selection depends on disease stage, patient factors and physician judgment.

Iodopol should be stored at ambient temperature below 25 °C, in its original packaging, protected from moisture and direct light. Keep the product out of reach of children and handle it according to local radiation safety regulations. Do not refrigerate unless specifically instructed by the supplier.

Iodopol is administered orally as a single dose, usually in capsule or liquid form, under the supervision of a qualified healthcare professional. The exact administration instructions, including any fasting requirements or timing relative to other medications, are provided by the prescribing clinician.

Serious risks include severe radiation thyroiditis, which can cause painful inflammation of the gland, and bone marrow suppression that may lead to anemia, infection or bleeding tendencies. Rarely, allergic reactions or pulmonary fibrosis have been reported. Patients should be monitored closely for these events during and after therapy.

Iodopol is contraindicated in individuals with known hypersensitivity to sodium iodide, pregnant women, nursing mothers, and patients with severe iodine deficiency or uncontrolled thyroid storm. It should also be used with caution in those with impaired renal function or existing bone marrow disorders, after thorough clinical evaluation.